ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LBRX / news
KARD (46) OPK (40) DMRA (35) NKTR (20) ⌘ Pro Terminal →

Why LBRX Stock slipped -1.66% Today — RQD Quant Desk Flash

$39.04 -1.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $38.85

LB Pharmaceuticals Inc (LBRX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.28B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LBRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, LB Pharmaceuticals Inc (NASDAQ: LBRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $39.04 (-1.66% 1D, market cap $1.28B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LBRX ranks #482 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LBRX compare to KARD and OPK in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LBRX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -8.4%. By comparison, KARD (Kardigan Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $1.32B) and OPK (OPKO Health Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -10.2%, cap $1.24B). Among the 5-stock peer group, LBRX leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LBRX?
▼

Per LBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001691082), LB Pharmaceuticals Inc generated $131.4M in revenue (+833.2% YoY), -$25.2M in net income, and -$35.3M in free cash flow against $312.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $38.85 (-0.49%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510039
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (5)Whales (11)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
$53 Bull$36 Base$28 Bear
📬 FREE LBRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LBRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY LBRX SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
31
Grade E$34.79+17.8% Next Q
Q2 (-2Q)
34
Grade E$41.00-3.3% Next Q
Q3 (-1Q)
36
Grade E$39.64-1.5% Next Q
Current
39
Grade D-$39.04-7.6% Hist 90D α
Trajectory: E (31) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LBRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LBRX currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($41.06) and Max Pain ($40.99) forces dealer call-delta covering toward $52.67.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LBRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LBRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why LBRX Stock slipped -1.66% Today — RQD Quant Desk Flash

LB Pharmaceuticals Inc (LBRX) slipped -1.66% to $39.04, trading at 69% of its 52-week range ($14.32 – $50.16). Stretched risk/reward at current multiples (-8% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 69% of its 52-week range ($14.32 – $50.16) with RSI-14 at 52.6 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $39.04 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live LBRX Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LBRX)

  • ✓Walkthrough of LBRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LBRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +22.65%⚡ TESTING RESISTANCE
2026-11-03O $40.15H $40.15L $39.04C $39.04VOL 429.5K
RES: $40.44SUP: $34.50SMA50: $41.06SMA200: $32.77
$52.20$43.76$35.32$26.88$18.44RES $40.44SUP $34.50$39.042026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LBRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LBRX Butterfly Map → + Track LBRX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +833.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LBRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LBRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LBRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LBRX)

Health Care Rank #482 of 1015 ⚔️ KARD vs LBRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LBRX vs. KARD, OPK, DMRA, NKTR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, LB Pharmaceuticals Inc (LBRX) ranks #482 by composite RQD confidence (39/100, grade D-) and #325 by equity capitalization ($1.28B). Within this direct 5-issuer industry benchmark cohort, LBRX leads on earnings valuation at N/A trailing P/E, while LBRX leads on capital efficiency and profitability with -8.4% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with LBRX at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LBRX ACTIVE
LB Pharmaceuticals Inc
D- 39/100 — — -8.4% -1.66% $1.28B Benchmark Subject
KARD
Kardigan Inc.
D 46/100 — — — +0.57% $1.32B /kard-vs-lbrx →
OPK
OPKO Health Inc.
D- 40/100 — 33.9% -10.2% +3.61% $1.24B /opk-vs-lbrx →
DMRA
Damora Therapeutics Inc.
D- 35/100 — — -35.0% +0.51% $1.33B /dmra-vs-lbrx →
NKTR
Nektar Therapeutics
E 20/100 — 96.0% -35.0% -4.94% $1.33B /nktr-vs-lbrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001691082 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LB Pharmaceuticals Inc (LBRX) reported GAAP revenue of $131.4M (+833.2% vs. FY2024 revenue of $14.1M ) , GAAP net income of -$25.2M, operating cash flow of -$35.2M, and free cash flow of -$35.3M (+34.5% YoY). On the balance sheet, LBRX closed FY2025 with $312.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $131.4M -$25.2M -$35.2M -$35.3M $312.9M —
FY2024 (FY) 2024-12-31 $14.1M -$63.1M -$53.1M -$53.8M $33.5M —

3. LBRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LBRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, LB Pharmaceuticals Inc (NASDAQ: LBRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $39.04 (-1.66% 1D, market cap $1.28B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LBRX ranks #482 in composite RQD confidence.

How does LBRX compare to KARD and OPK in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LBRX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -8.4%. By comparison, KARD (Kardigan Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $1.32B) and OPK (OPKO Health Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -10.2%, cap $1.24B). Among the 5-stock peer group, LBRX leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LBRX?

Per LBRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001691082), LB Pharmaceuticals Inc generated $131.4M in revenue (+833.2% YoY), -$25.2M in net income, and -$35.3M in free cash flow against $312.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LBRX trading relative to its 50-day, 200-day, and 52-week technical levels?

LBRX last traded at $39.04 (-1.66% on volume of 466,456 shares), positioning the stock -4.92% below its 50-day simple moving average ($41.06) and +19.13% above its 200-day simple moving average ($32.77). Across its 52-week range of $14.32 to $50.16, LBRX sits at the 69.0% percentile with a 14-day RSI of 52.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($34.16 to $43.92).

Direct Sub-Reports: LBRX RQD Cockpit LBRX 12M Forecast LBRX Earnings & Move LBRX Dividends & DRIP LBRX Insiders & 13F LBRX Whale Options LBRX Profit Sankey LBRX News & Why
ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ SEC XBRL & RQD VERIFIED

LBRX — LB Pharmaceuticals Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

LB Pharmaceuticals Inc (LBRX) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $39.04 (-1.66% 1D, market capitalization $1.28B).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -8.4%, gross margin of —, operating margin of —, and free cash flow yield of -2.72%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

LB Pharmaceuticals Inc (LBRX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $1.3B. — regarding specific products, customers, or revenue model. Per the financials, reported revenue is — for both FY 2025 and FY 2024, indicating no reported revenue in the periods provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), LB Pharmaceuticals Inc (LBRX) reported $131.4M in annual revenue (up from $14.1M in FY2024, +833.2% YoY) and -$25.2M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($14.1M revenue, -$63.1M net income) through FY2025, LBRX scaled operating cash flow to -$35.2M and free cash flow to -$35.3M, backed by $312.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.72% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $14.32 – $50.16 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), LBRX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can LBRX sustain or expand its — operating margin and -8.4% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $131.4M and free cash flow of -$35.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LBRX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LBRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LB Pharmaceuticals Inc (LBRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LBRX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LBRX Bull vs. Bear Conversation Board — What's Your Call at $39.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LBRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LBRX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $50.42 (+27.0%)
📌 Pinned Debate

Institutional whale/13F flow scores 13 of 20, the strongest RQD pillar, and reported cash rose from $23.0M to $250.2M between FY 2024 a

Institutional whale/13F flow scores 13 of 20, the strongest RQD pillar, and reported cash rose from $23.0M to $250.2M between FY 2024 and FY 2025.. When you look under the hood at LBRX, Fundamental Cash Engine is 5/20 with 0.0% gross margins and -8.4% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (11/20) has been quietly accumulating below $50.16. My 12M target is $50.42.

ArenaChamp_24 🐂 BULL

@SiliconVal_Bull Agree on the RQD 39/100 quality, though with 1.0 beta I'm scaling in with half-size at $39.70 and keeping dry powder in case we test $36.92.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $32.95 (-17.0%)
Spot @ $39.70

With zero reported revenue, net losses of -$25.2M in FY 2025 and -$63.1M in FY 2024, ROIC of -8.4%, and an FCF yield of -2.72%, the fun

Fading this rally in LBRX at $39.70. With zero reported revenue, net losses of -$25.2M in FY 2025 and -$63.1M in FY 2024, ROIC of -8.4%, and an FCF yield of -2.72%, the fundamental cash engine scores only 5 of 20.. With a beta of 1.0 and the stock sitting at $39.70 (52-wk range $14.32–$50.16), the easy multiple expansion is already priced in.

LIVE TAPE